Your browser doesn't support javascript.
loading
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
Jänne, P A; Smith, I; McWalter, G; Mann, H; Dougherty, B; Walker, J; Orr, M C M; Hodgson, D R; Shaw, A T; Pereira, J R; Jeannin, G; Vansteenkiste, J; Barrios, C H; Franke, F A; Crinò, L; Smith, P.
Afiliación
  • Jänne PA; Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
  • Smith I; AstraZeneca, Alderley Park, Macclesfield SK10 4TF, UK.
  • McWalter G; AstraZeneca, Alderley Park, Macclesfield SK10 4TF, UK.
  • Mann H; AstraZeneca, Alderley Park, Macclesfield SK10 4TF, UK.
  • Dougherty B; AstraZeneca, Gatehouse Park, Waltham, MA 02451, USA.
  • Walker J; AstraZeneca, Alderley Park, Macclesfield SK10 4TF, UK.
  • Orr MC; AstraZeneca, Alderley Park, Macclesfield SK10 4TF, UK.
  • Hodgson DR; AstraZeneca, Alderley Park, Macclesfield SK10 4TF, UK.
  • Shaw AT; Department of Medicine, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA.
  • Pereira JR; Instituto Brasileiro de Cancerologia Torácica, Rua Dr. Martinico Prado, 26/101, Higienópolis, Sao Paulo 01224-010, Brazil.
  • Jeannin G; Department of Pneumology, Hôpital Gabriel Montpied, 58 Rue Montalembert, 63000 Clermont-Ferrand, France.
  • Vansteenkiste J; Department of Pneumology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
  • Barrios CH; Department of Medicine, PUCRS School of Medicine, Padre Chagas 66, 203, Porto Alegre RS 90 570 080, Brazil.
  • Franke FA; CACON, Hospital de Caridade de Ijuí, Avenida David José Martins, 152-Centro, Ijuí RS 98700-000, Brazil.
  • Crinò L; Department of Oncology, University Medical School Perugia, Piazza Università 1, 06123 Perugia, Italy.
  • Smith P; AstraZeneca, Alderley Park, Macclesfield SK10 4TF, UK.
Br J Cancer ; 113(2): 199-203, 2015 Jul 14.
Article en En | MEDLINE | ID: mdl-26125448
ABSTRACT

BACKGROUND:

Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NCT00890825).

METHODS:

Retrospective analysis of OS, PFS, ORR and change in tumour size at week 6 for different sub-populations of KRAS codon mutations.

RESULTS:

In patients receiving selumetinib+docetaxel and harbouring KRAS G12C or G12V mutations there were trends towards greater improvement in OS, PFS and ORR compared with other KRAS mutations.

CONCLUSION:

Different KRAS mutations in NSCLC may influence selumetinib/docetaxel sensitivity.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Codón / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas / Carcinoma de Pulmón de Células no Pequeñas / Proteínas ras / Neoplasias Pulmonares / Mutación Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Codón / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas / Carcinoma de Pulmón de Células no Pequeñas / Proteínas ras / Neoplasias Pulmonares / Mutación Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos